Search
Cisplatin Treatment Options
A collection of 1429 research studies where Cisplatin is the interventional treatment. These studies are located in the United States. Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.
529 - 540 of 1429
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Recruiting
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/07/2023
Locations: City of Hope, Duarte, California +27 locations
Conditions: Ovarian Cancer
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
Completed
The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Pacific Shores Medical Group, Long Beach, California +109 locations
Conditions: Non-Small-Cell Lung Carcinoma
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Completed
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Local Institution - 0134, Tucson, Arizona +132 locations
Conditions: Head and Neck Cancer
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
Active Not Recruiting
This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC) patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be resistant to standard Radiation Therapy (RT) using DCE-MRI (Dynamic Contrast Enhanced Magnetic Resonance Imaging). Standard doses of radiotherapy to the rest of the tissues and surrounding normal tissues will be maintained.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2023
Locations: Veterans Affairs (VA) Ann Arbor Healthcare System, Ann Arbor, Michigan +1 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
Completed
RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinorelbine, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Radiation therapy uses high-energy x-rays to kill tumor cells. Cisplatin may also make tumor cells more sensitive to radiation therapy. Giving chemotherapy and rad... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
08/28/2023
Locations: Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Malignant Mesothelioma
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Terminated
This phase II trial studies the side effects of durvalumab and chemotherapy before surgery in treating patients with variant histology bladder cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor ce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: Stanford Cancer Institute Palo Alto, Palo Alto, California
Conditions: Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
Terminated
This study will assess the safety and effectiveness of fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by systemic gemcitabine/cisplatin chemotherapy compared to gemcitabine/cisplatin alone, in patients with inoperable cholangiocarcinoma (CCA). Participants will be randomly assigned to one of the treatment groups and will receive study treatment for 6 months, followed by assessments every 3 months, as applicable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: City of Hope National Medical Center, Duarte, California +49 locations
Conditions: Cholangiocarcinoma
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
Completed
Multicenter, randomized, open-label, parallel group phase 2 study to assess the efficacy and tolerance of four combinations of CBP501, cisplatin, and nivolumab administered once every 21 days to patients with stage IV exocrine pancreatic cancer and WBC \< 10,000/mm3 at screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2023
Locations: Arizona Oncology Associates, PC-HOPE, Tucson, Arizona +19 locations
Conditions: Pancreatic Cancer Stage IV
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Terminated
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as recombinant EphB4-HSA fusion protein, paclitaxel albumin-stabilized nanoparticle formulation,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2023
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Terminated
This is a Phase 1b/2, open label, multicenter, safety and clinical activity study of avelumab in combination with chemotherapy as first-line treatment of adult patients with locally advanced or metastatic solid tumors. Initially, avelumab will be evaluated in combination with pemetrexed and carboplatin in patients with advanced non-squamous non-small cell lung cancer (NSCLC) (Cohort A1) and in combination with gemcitabine and cisplatin in patients with cisplatin-eligible urothelial (bladder) can... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2023
Locations: University of Arizona Cancer Center - North Campus, Tucson, Arizona +45 locations
Conditions: Non-small Cell Lung Cancer, Urothelial Cancer
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Completed
This study evaluates efficacy of TAK- 228 and TAK- 117 followed by cisplatin and nab paclitaxel in patients with metastatic triple negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/04/2023
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Triple Negative Breast Cancer
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
Completed
This study adopts a novel strategy for first-line treatment of osteosarcoma by combining chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF). Chemotherapy for localized disease comprises a 3-drug regimen (cisplatin, doxorubicin, and high-dose methotrexate). Chemotherapy for metastatic or unresectable disease comprises a cisplatin-based regimen that includes high-dose methotrexate, doxorubicin, i... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
08/03/2023
Locations: Rady Children's Hospital and Health Center, San Diego, California +4 locations
Conditions: Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
529 - 540 of 1429